ITGAX and COVID-19: There was an increased percentage of CD11c+ CXCR5- (DN2) cells at day 7 to 28 post vaccination in all groups, with a higher level in COVID-19 experienced than COVID-19-naïve PAD patients (Figures 4G; S5E).